Previous Article | Next Article ![]()
Journal of Virology, October 2006, p. 10270-10273, Vol. 80, No. 20
0022-538X/06/$08.00+0 doi:10.1128/JVI.01272-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Departments of Medicine (Neurology),1 Microbiology and Immunology,2 Physiology,3 Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada4
Received 16 June 2006/ Accepted 31 July 2006
|
|
|---|
|
|
|---|
Primary cultures of mouse cortical and hippocampus neurons were prepared from fetuses of pregnant CD-1 mice at embryonic day 17 (3). Over 95% of the cells expressed the neuronal marker MAP-2. Cells were infected with the CVS strain of rabies virus, and there was expression of rabies virus antigen in over 90% of the cells. CVS- and mock-infected cells were analyzed using trypan blue exclusion for viability (17) on days 1, 2, and 3 postinfection (p.i.). There was a progressive loss in the viability in the cultures over time for the CVS-infected compared with the mock-infected cultures (Fig. 1). By 48 h p.i., infected neurons showed condensations of nuclear chromatin and cytoplasmic shrinkage, indicating apoptosis. Positive TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling) staining was observed in CVS-infected neurons by 24 h p.i. and later increased. Expression of activated caspase 3 was demonstrated in CVS-infected cultured cells. Treatment with 25 µM Ac-Asp-Glu-Val aspartic acid aldehyde (DEVD-CHO), a caspase inhibitor, in CVS infection resulted in significant improvement in viability on days 1 to 3 (P < 0.002) (Fig. 1). There was loss of viability on days 1 to 3 p.i. in a dose-dependent manner for both ketamine- and MK-801-treated cortical cells at concentrations of 0 to 2 mM (data not shown), and 125 µM ketamine and 60 µM MK-801 were selected for evaluation with CVS-infected cultures. Neither ketamine nor MK-801 was observed to exert a neuroprotective effect on CVS-infected cultures (Fig. 2). At 1 and 2 days p.i. ketamine significantly reduced the viability of CVS-infected hippocampal neurons (P = 0.019 and 0.006, respectively), while MK-801 had no significant effect on CVS-infected neurons.
![]() View larger version (11K): [in a new window] |
FIG. 1. Viability of cultured neurons from the cerebral cortex (left) and hippocampus (right) with and without 25 µM DEVD-CHO, which is a caspase inhibitor, as assessed by trypan blue exclusion. DEVD-CHO exerted a marked neuroprotective effect on the cultures, resulting in viability similar to that in the mock-infected cultures. Error bars represent standard errors of the means.
|
![]() View larger version (28K): [in a new window] |
FIG. 2. Viability of mock- and CVS-infected cultured cortical (A, C) and hippocampal (B, D) neurons with and without treatment with 125 µM ketamine (A, B) and 60 µM MK-801 (C, D), as assessed by trypan blue exclusion. Ketamine did not improve viability of the CVS-infected neurons and actually reduced viability in CVS-infected hippocampal neurons at 24 and 48 h p.i. (B). MK-801 had no effect on the viability of the CVS-infected neurons. Error bars represent standard errors of the means.
|
![]() View larger version (14K): [in a new window] |
FIG. 3. Quantitative analysis of cytosolic calcium in CVS- and mock-infected cortical (left) and hippocampal (right) neurons in response to 50 mM KCl and 10 µM glutamate stimulations. Results are shown as glutamate stimulation relative to potassium stimulation. There were significantly lower levels of intracellular Ca2+ release in CVS-infected than in mock-infected neurons at 24 h in cortical neurons and at 24, 48, and 72 h in hippocampal neurons (*, statistical significance, P < 0.05; error bars, standard errors of the means).
|
![]() View larger version (23K): [in a new window] |
FIG. 4. Kaplan-Meier survival curves of the cumulative mortality in mice inoculated in the right hind limb footpad (A) and intracerebrally (B) with CVS and treated twice daily with vehicle (dashed lines) or ketamine (solid lines). Vehicle (footpad, n = 10; intracerebral, n = 8) and ketamine (footpad, n = 11; intracerebral, n = 10) treatment groups were compared using log rank tests, which indicated that there was no difference in the mortality rate between treatment groups (footpad, P = 0.53; intracerebral, P = 0.50). Counts of the number of infected neurons in various brain regions of moribund mice were taken after right hind limb footpad (C) and intracerebral (D) inoculation of CVS and twice daily treatment with vehicle or ketamine. Slides stained for rabies virus antigen were blinded, and the numbers of infected neurons were counted in three different fields of the same brain region using a high-power (40x) objective in areas with the most marked staining. Vehicle (footpad, n = 8; intracerebral, n = 3) and ketamine (footpad, n = 11; intracerebral, n = 6) treatment groups were compared using an unpaired t test (*, statistical significance, P < 0.05; error bars, standard errors of the means).
|
The present study confirms that rabies virus infection of primary neuron cultures induces caspase-dependent neuronal apoptosis. There was associated expression of the downstream executioner caspase 3, and the caspase inhibitor DEVD-CHO effectively inhibited rabies virus-induced neuronal cell death in the cultures. The noncompetitive NMDA antagonists ketamine and MK-801 did not provide neuroprotection of rabies virus-infected primary neurons. Much lower concentrations of MK-801 (3 µM) provided effective neuroprotection of Sindbis virus infection of rat primary cortical neurons (18). In our CVS-infected cultures, glutamate stimulation did not result in increased [Ca2+]i (Fig. 3). Accumulation of intracellular Ca2+ plays a critical role in the early stages of glutamate-induced neurotoxicity (4), and NMDA receptors play a key role in glutamate-induced neurotoxicity due to their high Ca2+ permeability (1). The [Ca2+]i indicates that excitotoxicity did not play an important role in the CVS-infected primary neuron cultures and indicates functional impairment of rabies virus-infected neurons, which is of unknown cause (6). Sustained glutamate overstimulation was not observed in association with the loss of viability and progressive neuronal death in the infected cultures. In contrast, Sindbis virus infection of rat primary cortical neurons is associated with an increased intracellular calcium concentration (18).
Ketamine (60 mg/kg every 12 h intraperitoneally) did not result in reduced mortality or amelioration of the clinical neurological disease in mice compared to administration of the vehicle, and ketamine did not inhibit viral spread in this model. There was no reduction in the number of infected neurons or the amount of infectious rabies virus in the CNS compared to that in mice receiving only vehicle. In contrast, Tsiang's group previously reported that the same dosage of ketamine inhibited viral spread after stereotaxic inoculation of rats with CVS (16). Virus entry using footpad inoculation better evaluates viral spread through the neuroaxis, and it is highly doubtful that there is a species-specific difference in the therapeutic effect of ketamine. The more comprehensive analyses used in the present study showed the lack of therapeutic efficacy of ketamine.
CVS infection of the brain is associated with widespread neuronal apoptosis after infection by the intracerebral route (11). Therapy with ketamine was not associated with neuroprotection, as assessed by evaluation of neuronal apoptosis in the brain. No beneficial effects of therapy were observed clinically, histopathologically, or by analysis of the viral spread in the mice.
These studies were performed with CVS, and it is unknown if street rabies virus variants have similar biological properties. The findings indicate that caution should be taken before subjecting future human rabies patients to therapy with ketamine on the basis of the previous experimental work (15, 16, 20). There have been at least four patients treated with ketamine after the survivor received ketamine in 2004, and all of these patients progressed to fatal outcomes (7). Hence, further experimental studies are needed to evaluate the efficacy of ketamine therapy in rabies virus infection before it becomes a standard therapy for human rabies.
This work was supported by Canadian Institutes of Health Research grant MOP-64376 and the Queen's University Violet E. Powell Research Fund (both to A. C. Jackson). S. C. Weli received support from a John Alexander Stewart Postdoctoral Fellowship from the Department of Medicine at Queen's University.
Supplemental material for this article may be found at http://jvi.asm.org/. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»